I like PTLA, plus CLVS, INCY and RDUS at that level.
I prefer to stay on the side line for now - above 70% in cash
Bought yesterday a bit NBIX ,- beaten too much down with meaningful catalysis by the end of the year, which may or may not help if the sell off continues in October.
I dont know the size of the market but it's an interesting setup. ATRS will only get paid a percentage for three years so one would expext that it will be a nice number and a very healthy milestone on approval. I think the three year period has to do with patent expiry on the gel.
The two phase 3 studies were competed this April, one on elbow, and the other on ankle. The product will be marketed in 2016. Advil is the best selling pain reliever, so does anyone have any guesses as to what kind of sales numbers pfizer could likely get?
haha lol...I made some on selling high but unfortunately added again later so am now in the loosing boat (not sold yet). If sold now it will be net neutrality for me. I am still holding till maybe early December when I might consider sweeping out a few of the losers for tax purposes.
Andre- are you still invested with PTLA? I still maintain a position there.
Anything that you think is strong but was beaten down after Hillary's tweet??
The only logical explanation is
1) He is not short (I think he is)
2) He has inside information like the Deerfields' of the world
If you know the approval won't be until February 2016, for arguments sake, then you would also know that 2.03 was resistance and that support is somewhere between 1.30 - 1.50 based on almost no credit of FDA approval of generic EPI (AB) which can be 'justified' by the controlling influences of the stock because of the lengthy delay. The news of it would propel us from 1.50 to 3 rather quickly, perhaps same day. I am sure wicked will cover his short and go long just before the news comes to us.
ATRS's team are the ones who hand picked June 2015 for Epi-pen AB approval? I didn't know ATRS management also runs the giant pharma company TEVA & Mylan and also had the Judge in their back pocket! You are bizarre for some of the stuff I've read from your posts.
"In my opinion"
"ATRS picked June 2015"
First your opinion is worth 0
Second I assume that June 2015 is the date in the settklement between TEVA and Pfizer. ATRS did anot pick any June date ATRS does not pick anything as far as EPI goes it's not an ATRS product.
You are spreading faulty information and innuendo on par with andre_y_mb, maybe that is more than a coincidence........I'm sure Ryman can straighten that out.
Actually the June 2015 date was set by the agreement on the settled suit between pfizer, mylan, and teva. That was the earliest date by which teva could start selling an AB rated epipen. Also if you think teva will get AB rating, why would you risk the stock being halted on the news and your short implodes.
What makes you so sure the FDA will not make the decision this year? It was said by TEVA and ATRS late in the game that 2H is when we can expect feedback from the FDA. We still have 3 months, but I would imagine with the christmas holiday more like 2 months to get it done this year.
We know management has plain and simply 'sucked', but what does that have to do with the approval of a Generic EPI-PEN which has nothing to do with ATRS and everything to do with TEVA? Do you not agree, regardless of the managements self greed, that a Generic EPIPEN (AB rated) will propel this stock to at least a double up and then consolidate before it starts to work its way into the 4's and 5's in the next 12-18 months?
The latest PR sort of summed up what ATRS has been doing for years and that is:
* hype up a new product then
* get paid a bonus for getting it cycled then
* do a round of stock dilution to promote new product then
* cash in on another bonus while promoting another new product
Wash, Rinse, Repeat. Don't believe this? Then look at the last 40 months and see if it tells a different story. It looks as some retail investors have caught on. But not the few who frequent here :)
And to answer your question on why PW left. He had his moments in the Sun, while cashing in on unworthy work and seen the writing on the wall. Stock price when he was in office...$3.50. Today...$1.68 and sinking fast.
and the company is lacking the leadership to maximize profits. I would love to know why the CEO left this company months ago, the real reason. I hope the company finds itself and reaches its potential. Critics and analysts have been positive about the company for years and that's why the market cap was way above what the company was really worth, especially based on revenue and lack of profits. This can't continue much longer and the drop in price reflects the frustrations of the investor over the years. I really hope things turn around Good luck.
S&P up 1.5%
IBB up 4%
SYN up 10%
AVXL up 7%
OHRP up 4%
ATRS down 1% hmmm.....